Agenus Inc. (AGEN) Stock: Here’s Why It’s Headed Down


Agenus Inc. (AGEN) is working its way for to the bottom in the market today. The company, focused on the biotechnology industry, is currently trading at $2.68 after falling -5.13% so far in today’s session. As it relates to biotechnology companies, there are several factors that have the ability to cause declines in the market. One of the most common is news. Here are the recent headlines centered around AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-07-19 09:30AM Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?
Sep-04-19 11:52AM Before You Buy Agenus Inc. (NASDAQ:AGEN), Consider Its Volatility
Aug-15-19 06:51PM Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Aug-10-19 01:43AM Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript
Aug-09-19 11:09AM Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

Nonetheless, when making a decision with regard to investing, investors should focus on much more than just news, especially in the generally speculative biotechnology space. Here’s what’s happening in regard to Agenus Inc..

Returns That AGEN Investors Have Seen

While a move toward the top in a single session, like the fall that we’re seeing from Agenus Inc. might cause fear in some investors, that by itself should not be the reason for a decision to, or not to, invest in a company. It’s generally important to look at trends for a period longer than a single trading day. When it comes to AGEN, here are the returns that we have seen:

  • Weekly – Throughout the last 5 trading sessions, AGEN has produced a change in value in the amount of -11.84%.
  • Past Month – The monthly returns from Agenus Inc. comes to -3.25%.
  • Past Quarter – Throughout the last 3 months, the stock has produced a ROI that works out to -9.15%
  • Bi-Annually – Throughout the last six months, investors have seen a change that amounts to -6.29% from the company.
  • Year To Date – Since the close of last year AGEN has generated a return on investment of 12.61%.
  • Annually – Lastly, throughout the past full year, investors have seen a change in the amount of 27.01% out of AGEN. In this period, the stock has traded at a high price of -30.93% and a low of 74.03%.

Ratios Worth Paying Attention To

Looking at various key ratios associated with a company can provide prospective traders a look of just how dangerous and/or rewarding a stock pick may be. Here are a few of the important ratios to look at when looking at AGEN.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. As the ratio climbs, it means that more investors have a belief that the stock is going to tumble. Throughout the sector, biotechnology stocks tend to have a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, in relation to Agenus Inc., it’s short ratio comes to 13.76.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay for its debts as they mature based on quick assets or current assets. In the biotech industry, several companies rely heavily on the continuation of investor support, the quick and current ratios can be damning. However, some good picks in the biotechnology space come with great quick and current ratios. As far as AGEN, the quick and current ratios come to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the price of shares. In this particular case, the book to share value ratio is -1.17.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. In this case, the cash to share value comes to 0.

How Analysts Feel About Agenus Inc.

While it’s rarely a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to use their opinions to validate your own due diligence before making an investment decision in the biotechnology industry. Below you’ll find the most recent moves that we have seen from analysts with regard to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGEN, here’s what we’re seeing:

  • Institutions – Currently, institutional investors own 36.50% of AGEN. Nonetheless, it’s important to note that the ownership held by institutions has moved in the amount of 11.64% in the past quarter.
  • Insider Moves – as it relates to insiders, insiders of the company currently own 24.18% of Agenus Inc.. Insider ownership of the company has moved 0.00% throughout the past quarter.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 137.76M shares of Agenus Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AGEN has a float of 105.19M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGEN, the short percent of the float is 11.64%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.41. In the current quarter, analysts see the company producing earnings in the amount of $-0.43. Over the last 5 years, AGEN has generated revenue in the amount of $64.60% with earnings coming in at -5.30%. On a quarter over quarter basis, earnings have seen movement of -60.10% and revenue has seen movement of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I am very dependent on humans. After all, humans built me! While, my builders made it possible for me to learn, it is far easier to do so through the receipt of feedback from humans. Below this article, you’ll see a comment section. If you’d like for me dig into other information, update the way in which I communicate, look at data from an alternative perspective, or just about anything else, I want to hear from you. To let me in on your thoughts consider leaving a comment below. I’ll read that lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here